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Originating	Technology/NASA	Contribution
For	decades	now,	NASA	has	been	sending	spacecraft	throughout	the	galaxy.	Once	in	the	cosmos,	these	crafts	use	advanced	cameras	 to	create	 images	of	
corners	and	crevices	of	our	universe	never	before	seen	and	
then	transmit	these	pictures	back	to	laboratories	on	Earth,	
where	government	scientists	then	ask	themselves:	What 
exactly are we looking at?
That	question	is	answered	at	NASA’s	Jet	Propulsion	
Laboratory	(JPL)	 in	the	Image	Processing	Laboratory,	
founded	in	1966	to	receive	and	make	sense	of	spacecraft	
imagery.	There,	NASA-invented	VICAR	(Video	Image	
Communication	and	Retrieval)	software	has,	through	the	
years,	laid	the	groundwork	for	understanding	images	of	
all	kinds.	The	original	software,	created	by	a	JPL	team	of	
three,	Robert	Nathan,	Fred	Billingsley,	and	Robert	Selzer,	
is	in	use	even	to	this	day,	although	with	greater	accuracy	
and	effectiveness	due	to	decades	of	advancements.		
The	imaging	division	at	JPL	has	grown	increasingly	
sophisticated	over	the	years,	developing	new	processes	and	
technologies	to	handle	increasingly	complex	acquisitions	
from	each	NASA	space	mission,	from	the	Voyager	images	
of	Saturn	and	Jupiter	 taken	 in	 the	1970s,	 to	 the	new	
imagery	captured	by	the	Mars	Reconnaissance	Orbiter	in	
late	2006	that	suggests	water	still	flows	on	Mars,	opening	
the	possibility	that	the	Red	Planet	could	perhaps	support	
some	forms	of	life.
Partnership
Selzer,	from	the	original	VICAR	team,	has	made	the	
NASA	imaging	technology	his	life’s	work,	spending	46	
years	as	a	NASA	employee	and	continuing	to	work	on	its	
advancement	even	after	his	retirement	from	JPL.	Selzer	
received	many	NASA	awards	for	technical	achievement,	
including	the	prestigious	Technology	and	Application	
Program	Exceptional	Achievement	Medal.
During	 the	 last	15	years	of	his	 career	 as	 a	govern-
ment	scientist,	he,	as	head	of	the	JPL	Biomedical	Image	
Processing	Laboratory,	was	working	on	using	the	imaging	
technology	for	health	care	diagnosis.	
The	project	began	when	the	imaging	team	developed	
the	idea	of	using	the	VICAR	software	to	analyze	X-ray	
images	of	soft	tissue.	Typically,	the	X-ray	is	ineffective	
when	used	to	analyze	soft	tissues,	though	the	researchers	
were	curious	to	see	if	the	imaging	software	could	broaden	
the	application	of	this	readily	available	diagnostic	proce-
dure.	The	results	were	interesting,	but	too	much	quality	
was	lost	in	transferring	the	pictures	into	a	digital	format	
for	analysis.	Still,	the	idea	seemed	feasible,	so,	with	several	
grants	from	NASA,	the	testing	continued.	
Selzer’s	JPL	team,	partnering	with	scientists	from	the	
University	of	Southern	California	under	the	direction	
of	 the	 late	Dr.	David	Blankenhorn	 and	Dr.	Howard	
Hodis,	director	of	the	Atherosclerosis	Research	Unit	at	
the	school’s	Keck	School	of	Medicine,	began	to	image	
X-rays	of	arteries.	With	marginal	success	using	X-rays,	
they	came	upon	the	idea	of	using	the	same	methodology	
but	applying	it	to	ultrasound	imagery,	which	was	already	
digitally	formatted.	The	new	approach	proved	successful	
for	assessing	amounts	of	plaque	buildup	and	arterial	wall	
thickness,	direct	predictors	of	heart	disease.	
Testing	 continued,	 and	 the	 team,	 buoyed	 by	 its	
successes,	began	looking	for	outside	funding	and	methods	
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of	distribution.	At	this	point,	Gary	F.	Thompson	entered	
the	picture.	
Thompson	has	a	history	of	heart	disease	in	his	family.	
The	first	male	in	many	generations	to	live	past	age	50,	and	
the	last	living	male	in	his	family	line,	Thompson	comes	
from	a	long	line	of	active,	athletic	men	who,	with	no	prior	
symptoms,	suffered	fatal	heart-related	events.	A	lifelong	
athlete	who	had	boxed	 in	 the	New	York	City	Golden	
Gloves	tournament	in	his	youth	and	ran	his	first	marathon	
in	1975,	Thompson	was	understandably	concerned,	but	
feeling	confident,	when	he	approached	his	50th	birthday.	
He	had	the	family	history	working	against	him,	but	he	was	
also	in	prime	shape.	To	celebrate	his	half-century	mark,	
he	planned	to	run	three	marathons:	Los	Angeles,	New	
York,	and	Boston,	and	he	underwent	a	battery	of	medical	
tests,	all	of	which	confirmed	that	he	was	in	perfect	health,	
without	any	signs	of	cardiovascular	disease.
Seven	days	after	his	birthday,	Thompson	ran	the	Los	
Angeles	marathon.	At	the	15th	mile,	he	started	experienc-
ing	back	pain.	By	the	20th	mile,	it	became	so	excruciating,	
that	he	stopped	running	and	sought	the	help	of	a	police	
officer	who	was	monitoring	the	race.	Later,	at	the	hospi-
tal,	doctors	confirmed	that	he	had	suffered	a	moderate	
heart	attack	and	lost	48	percent	of	his	heart	muscle.	The	
modern	medical	 testing,	 he	 realized,	 had	 failed	 him.	
Luckily	for	Thompson,	compared	to	most	men	his	age,	
for	him	to	have	52	percent	of	his	heart	working	was	the	
equivalent	of	127	percent,	because	he	was	so	athletic.		
Months	later,	at	dinner	with	David	Baltimore,	then	
president	 of	 the	 California	 Institute	 of	 Technology	
(Caltech),	 Thompson	 asked	 whether	 there	 were	 any	
new	 heart-related	 breakthroughs	 from	 the	 esteemed	
university	and	was	surprised	to	hear	that	there	actually	
was,	indeed,	a	new	technology,	but	that	it	had	been	devel-
oped	at	JPL.	It	was	a	noninvasive	diagnostic	system	with	
the	ability	to	accurately	predict	heart	health.	Baltimore	
offered	to	set	up	an	appointment	for	Thompson	at	the	
University	of	Southern	California	hospital	where	this	new	
method	was	being	tested,	but	Thompson	declined	the	
privileged	treatment.
Instead,	he	went	in	on	his	own,	unannounced,	and	
without	revealing	his	family	history	or	recent	heart	attack.	
Thompson,	who,	despite	 the	 recent	 event,	gave	every	
impression	of	great	health,	met	with	a	technician,	who	
asked	him	to	 loosen	his	collar	and	then	performed	an	
ultrasound	scan	on	either	side	of	his	neck,	the	location	
of	the	carotid	arteries.	When	the	results	were	in,	the	tech-
nician	told	Thompson	that	he	needed	to	meet	with	the	
doctor	immediately.	The	test	showed	that	Thompson	had	
the	thickest	artery	walls	of	the	over	3,000	other	people	
tested,	a	direct	indicator	that	he	was	in	danger	of	a	heart	
attack	or	stroke.		
Thompson	was	impressed.	This	new	device	had	man-
aged	to	do	what	all	of	the	other	tests	had	failed	to	do:	give	
him	an	accurate	reading	of	his	heart	health.	Thompson,	
a	hard-charging	 entrepreneur,	met	with	 the	 research-
ers	Selzer	and	Hodis	and	told	them	that	they	needed	to	
get	this	technology	into	the	hands	of	physicians.	They	
agreed.	Thompson	developed	a	business	plan,	secured	an	
exclusive	license	for	the	JPL-developed	technology	from	
Atherosclerosis is a condition in which fatty material collects along the walls of arteries. This fatty material thickens, hardens, 
and may eventually block the arteries.
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Caltech,	and	invested	his	own	money	to	start	Medical	
Technologies	International	Inc.	(MTI),	located	in	Palm	
Desert,	California.	Selzer,	after	retiring	from	JPL,	joined	
in	and	now	serves	as	the	company’s	chief	engineer.	
Product	Outcome
MTI	 licensed	 14	 research	 institutions	 around	 the	
world	for	pre-U.S.	Food	and	Drug	Administration	(FDA)	
clearance,	research-only	use	of	the	analysis	software	and	
then	incorporated	feedback	from	these	groups	into	the	
new	clinical	product	it	was	developing.	It	patented	the	
new	developments	and	then	submitted	the	technology	to	
a	rigorous	review	process	at	the	FDA,	which	cleared	the	
device	for	public	use.	MTI	also	filed	with	the	American	
Medical	Association	to	have	the	device	given	a	dedicated	
Current	Procedural	Technology	(CPT)	code	for	insurance	
purposes,	thus	encouraging	more	doctors	to	offer	this	test	
to	patients.	
The	 patented	 software	 is	 being	 used	 in	 MTI’s	
ArterioVision,	a	carotid	intima-media	thickness	(CIMT)	
test	that	uses	ultrasound	image-capturing	and	analysis	
software	to	noninvasively	identify	the	risk	for	the	major	
cause	of	heart	attack	and	strokes:	atherosclerosis.
The	 term	 atherosclerosis	 comes	 from	Greek,	with	
athero	meaning	a	gruel	or	paste	(plaque)	and	sclerosis	
meaning	hardness.	It	is	just	that,	a	buildup	of	cholesterol	
and	 fatty	 substances	 in	 the	 arteries,	 combined	 with	
arterial	hardening.	The	result	is	that	blood	flow	through	
the	heart	is	restricted,	hampering	oxygen	supply.	Heart	
attacks	occur	when	the	heart	does	not	get	the	necessary	
oxygen,	and	strokes	are	the	result	of	oxygen	not	reaching	
the	brain.	Atherosclerosis,	referred	to	by	the	American	
Heart	Association	(AHA)	as	the	“silent	killer,”	initially	
has	 no	 discernable	 symptoms	 until	 one	 or	 more	 of	
the	 arteries	 becomes	 so	 congested	 that	 these	 major,	
sometimes	fatal,	problems	occur.	The	AHA	estimates	that	
two	out	of	three	unexpected	cardiac	deaths	occur	without	
prior	symptoms.
In	fact,	astronaut	Edward	White,	the	first	astronaut	
to	ever	perform	a	space	walk,	and	one	of	the	three	space	
pioneers	to	die	during	the	Apollo	launch	pad	tragedy	in	
1967,	was	thought	by	most	to	be	in	perfect	health,	having	
successfully	passed	all	of	the	rigorous	astronaut	testing.	
An	autopsy	directly	after	the	accident,	though,	revealed	
that	he	had	extreme	thickening	of	the	arteries	and	showed	
most	signs	of	heart	disease.	With	this	particular	disease,	
though,	as	has	been	mentioned	previously,	often	the	only	
symptoms	are	either	heart	attack	or	stroke.
ArterioVision	provides	a	direct	measurement	of	athero-
sclerosis	before	it	causes	these	“symptoms”	by	safely	and	
painlessly	measuring	the	thickness	of	the	first	two	layers	
of	the	carotid	artery	wall	using	an	ultrasound	procedure	
and	advanced	image-analysis	software.	The	carotid	artery,	
located	on	both	sides	of	the	neck,	is	the	largest	artery	that	
is	near	the	surface	of	the	skin.	It	supplies	blood	to	the	
brain,	and	it	can	therefore	be	examined	noninvasively.	
ArterioVision	essentially	performs	a	skin	surface	imaging	
“biopsy”	to	examine	the	arterial	wall.	
ArterioVision is the only CIMT tool on the market that offers 
a predictive report for physicians and patients. It explains 
the significance of test results using a proprietary database 
and JPL-developed algorithms and can extrapolate to show 
percentile of risk.
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As	 evidenced	 by	 the	 battery	 of	 tests	 Thompson	
underwent	 before	 his	 heart	 attack,	 diagnostic	 tools	
for	 atherosclerosis	 screening	 are	 far	 from	 advanced.	
Atherosclerosis	 begins	 in	 the	 abdomen	 and	 ascends	
to	the	heart	and	the	carotid	arteries.	A	diagnostic	tool	
for	 examining	 it	 in	 the	abdomen	 is	 the	computerized	
tomography	(CT)	scan,	but	CT	comes	with	a	certain	level	
of	risk	and	at	a	great	financial	cost.	Unlike	ultrasound,	
which	is	safe	enough	that	it	is	used	on	unborn	babies,	
CT	scans	rely	on	radiation	to	produce	results.	While	this	
procedure	is	still	new	enough	that	the	risks	are	relatively	
unknown,	the	National	Toxicology	Program,	a	division	
of	the	U.S.	Department	of	Health	and	Human	Services,	
has	 recently	 declared	 X-rays	 carcinogenic.	 Similarly,	
researchers	at	Columbia	University	have	estimated	that	
radiation	for	a	 full-body	scan	 is	roughly	equivalent	to	
the	same	amount	of	radiation	exposure	experienced	by	
people	within	1.5	miles	of	the	atomic	bombs	dropped	
on	Nagasaki	and	Hiroshima.	In	other	terms,	it	is	roughly	
equivalent	to	the	radiation	from	200	chest	X-rays.	As	an	
added	disadvantage,	X-ray	machines	and	the	production	
of	radiation	cost	a	great	deal	of	money.	
The	NASA-based	technology	has	none	of	these	prob-
lems.	It	poses	no	risks,	and	it	is	relatively	inexpensive.	The	
imaging	technology	can	distinguish	between	256	different	
shades	of	gray	and	differentiate	nuances	at	a	sub-pixel	level	
of	interpolation,	making	it	the	most	accurate	in	this	field,	
and	it	is	compatible	with	all	existing	ultrasound	machines,	
making	it	more	readily	accessible	to	physicians.	
While	 ArterioVision	 is	 not	 the	 only	 FDA-cleared	
CIMT	tool	on	the	market,	it	is	the	only	one	that	offers	a	
predictive	report	for	the	physician	and	patient.	It	explains	
the	significance	of	test	results	using	a	proprietary	database	
and	JPL-developed	algorithms,	and	can	extrapolate	to	
show	percentile	of	risk.
One	particular	feature	of	the	report	is	the	revelation	of	
arterial	age.	It	can	show	the	patient	that	while	he	may	be	
50	years	old,	his	arteries	may	be	the	equivalent	of	patients	
75	 years	 old.	 This	 real-world	 number	 is	 something	
patients	can	identify	with	and	helps	promote	compliance	
with	drug	therapies	and	other	forms	of	treatment—one	
of	the	most	difficult	aspects	of	preventing	and	treating	
heart	disease.	Physicians	often	lament	that	they	stress	the	
importance	of	lifestyle	changes	to	their	patients,	but	since	
heart	disease	does	not	initially	come	with	symptoms,	but	
instead	with	potentially	fatal	events,	it	is	often	difficult	to	
impress	upon	the	patients	the	urgency	of	taking	care	of	
their	hearts.	The	ArterioVision	patient	report	provides	a	
significant	warning	sign	and	gives	concrete	examples.	
The	report	then	becomes	part	of	a	serial	examination.	
Atherosclerosis	 can	 be	 reversed	 with	 strategies	 like	
exercise,	diet	change,	weight	loss,	smoking	cessation,	and	
cholesterol-lowering	medication;	and	the	patient	can	see,	
after	implementing	a	new	strategy,	if	that	one	is	working.
Currently,	the	technology	is	in	all	50	states,	and	in	
many	countries	throughout	the	world.	MTI	is	continuing	
to	push	this	life-saving	technology	and	is	rapidly	expand-
ing	its	sales	force	in	an	effort	to	live	up	to	its	company	
credo,	“Making	a	Positive	Difference	Every	Day.”	v
ArterioVision™	is	a	trademark	of	Medical	Technologies		
International	Inc.
ArterioVision is a CIMT test that uses ultrasound image-capturing and analysis software to noninvasively identify the risk for the 
major cause of heart attack and strokes: atherosclerosis.
